"TBSF" Human Immunoglobulin for Intravenous Use

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

normal immunoglobulin, Quantity: 60 g/L

Disponível em:

CSL Behring Australia Pty Ltd

DCI (Denominação Comum Internacional):

normal immunoglobulin

Forma farmacêutica:

Injection, solution

Composição:

Excipient Ingredients: maltose

Via de administração:

Intravenous

Unidades em pacote:

50mL, 200mL

Classe:

Medicine Listed (Export Only)

Tipo de prescrição:

(S1) This Schedule is intentionally blank

Indicações terapêuticas:

TBSF Human Immunoglobulin for Intravenous Use is indicated for replacement IgG therapy in: * primary immunodeficiency (PID) * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. TBSF Human Immunoglobulin for Intravenous Use is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count * allogeneic bone marrow transplantation * Kawasaki disease * Guillain-Barre Syndrome (GBS).

Resumo do produto:

Visual Identification: Clear, colourless solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Status de autorização:

Listed (Export Only)

Data de autorização:

2006-03-01